Table 3 Clinicopathological features of patient and healthy controls in the present study
| Â | Plasm methylome | Tissue qMSP | Plasm BSP | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | HC1 | CHB2 | LC3 | HCC4 | NSCLC5 | HC1 | LC3 | HCC4 | HC1 | CHB2 | LC3 | HCC4 |
Cases | 31 | 30 | 27 | 29 | 26 | 10 | 29 | 33 | 37 | 36 | 40 | 47 |
Gender | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Male | 28 (90.3%) | 27 (90.0%) | 24 (88.9%) | 26 (89.7%) | 23 (88.5%) | 6 (60%) | 25 (86.2%) | 27 (84.9%) | 30 (81.1%) | 28 (77.6%) | 33 (78.8%) | 39 (83.0%) |
 Female | 3 (9.7%) | 3 (10.0%) | 3 (11.1%) | 3 (10.3%) | 3 (11.5%) | 4 (40%) | 4 (13.8%) | 6 (15.1%) | 7 (18.9%) | 8 (22.2%) | 7 (21.2%) | 8 (17.0%) |
Age | 50.3 ± 8.6 | 50.7 ± 7.6 | 50.8 ± 9.6 | 55.8 ± 8.5 | 52.4 ± 9.6 | 42.2 ± 6.53 | 46.9 ± 9.2 | 50.3 ± 9.1 | 53.32 ± 5.3 | 52.53 ± 4.7 | 48.89 ± 10.7 | 54.29 ± 8.3 |
HBV infection | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Yes | 0 (0%) | 30 (100%) | 27 (100%) | 29 (100%) | 0 (0%) | 0 (0%) | 30 (100%) | 33 (100%) | 0 (0%) | 36 (100%) | 40 (100%) | 47 (100%) |
 No | 31(100%) | 0 (0%) | 0 (0%) | 0 (0%) | 29 (100%) | 10(100%) | 0 (0%) | 0 (0%) | 37 (100%) | 0 (0%) | 0 (0%) | 0 (0%) |
Differentiation | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Poor |  | / | / | 11 (37.9%) | 12 (46.2%) | / | / | 15 (45.5%) | / | / | / | 22 (46.8%) |
Moderate | Â | / | / | 10 (34.5%) | 8 (30.7%) | / | / | 13 (39.4) | / | / | / | 15 (31.9%) |
 High |  | / | / | 8(27.6%) | 6 (23.1%) | / | / | 5 (15.1%) | / | / | / | 10 (21.3%) |
Tumor stage | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 I/II |  | / | / | 14 (48.3%) | 10 (38.5%) | / | / | 13 (39.4%) | / | / | / | 12 (25.5%) |
 III/IV |  | / | / | 15 (51.7) | 16 (61.5%) | / | / | 20 (60.6%) | / | / | / | 35 (74.5%) |
Tumor size | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 ≤3cm |  | / | / | 16 (55.2%) | / | / | / | 11 (33.3%) | / | / | / | 16 (34.1%) |
 >3cm |  | / | / | 13 (44.8%) | / | / | / | 22 (66.7%) | / | / | / | 31 (65.9%) |